CN113727711A - 用于治疗肾脏疾病的新化合物及其药物组合物 - Google Patents

用于治疗肾脏疾病的新化合物及其药物组合物 Download PDF

Info

Publication number
CN113727711A
CN113727711A CN202080030725.9A CN202080030725A CN113727711A CN 113727711 A CN113727711 A CN 113727711A CN 202080030725 A CN202080030725 A CN 202080030725A CN 113727711 A CN113727711 A CN 113727711A
Authority
CN
China
Prior art keywords
compounds
compound
acid
treatment
cpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030725.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·E·康拉思
R·C·X·布里斯
T·J-C·M·克里斯托夫
R·范德格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN113727711A publication Critical patent/CN113727711A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080030725.9A 2019-04-24 2020-04-21 用于治疗肾脏疾病的新化合物及其药物组合物 Pending CN113727711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
GB1905711.6 2019-04-24
PCT/EP2020/061083 WO2020216740A1 (en) 2019-04-24 2020-04-21 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
CN113727711A true CN113727711A (zh) 2021-11-30

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030725.9A Pending CN113727711A (zh) 2019-04-24 2020-04-21 用于治疗肾脏疾病的新化合物及其药物组合物

Country Status (16)

Country Link
US (1) US12383544B2 (https=)
EP (1) EP3958863B1 (https=)
JP (1) JP7543304B2 (https=)
KR (1) KR20220004111A (https=)
CN (1) CN113727711A (https=)
AU (1) AU2020263869A1 (https=)
BR (1) BR112021021117A2 (https=)
CA (1) CA3137445A1 (https=)
ES (1) ES2982398T3 (https=)
GB (1) GB201905711D0 (https=)
IL (1) IL287392A (https=)
MA (1) MA55752A (https=)
MX (1) MX2021012544A (https=)
PH (1) PH12021552680A1 (https=)
SG (1) SG11202111739VA (https=)
WO (1) WO2020216740A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201305A1 (en) * 2024-03-26 2025-10-02 Alebund Pharmaceuticals (Hong Kong) Limited Method for treating autosomal dominant polycystic kidney disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096453A1 (en) * 2023-10-30 2025-05-08 Vertex Pharmaceuticals Incorporated Compounds for the treatment of kidney disease
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060047126A1 (en) * 2004-08-20 2006-03-02 Georg Gunda I Lonidamine analogues and their use in male contraception and cancer treatment
CN102695510A (zh) * 2009-08-10 2012-09-26 加利福尼亚大学董事会 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途
CN104334176A (zh) * 2012-05-31 2015-02-04 大塚制药株式会社 用于预防和/或治疗多囊肾病的药物
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
CN108513574A (zh) * 2015-10-09 2018-09-07 艾伯维公司 N-磺酰化吡唑并[3,4-b]吡啶-6-甲酰胺和使用方法
CN108602816A (zh) * 2015-10-09 2018-09-28 艾伯维公司 用于治疗囊性纤维化的新颖化合物
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
AU2016333855A1 (en) 2015-10-09 2018-04-26 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060047126A1 (en) * 2004-08-20 2006-03-02 Georg Gunda I Lonidamine analogues and their use in male contraception and cancer treatment
CN102695510A (zh) * 2009-08-10 2012-09-26 加利福尼亚大学董事会 囊性纤维化跨膜传导调节蛋白的嘧啶并-吡咯并-喹喔啉二酮抑制剂及其用途
CN104334176A (zh) * 2012-05-31 2015-02-04 大塚制药株式会社 用于预防和/或治疗多囊肾病的药物
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
CN108513574A (zh) * 2015-10-09 2018-09-07 艾伯维公司 N-磺酰化吡唑并[3,4-b]吡啶-6-甲酰胺和使用方法
CN108602816A (zh) * 2015-10-09 2018-09-28 艾伯维公司 用于治疗囊性纤维化的新颖化合物
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201305A1 (en) * 2024-03-26 2025-10-02 Alebund Pharmaceuticals (Hong Kong) Limited Method for treating autosomal dominant polycystic kidney disease

Also Published As

Publication number Publication date
IL287392A (en) 2021-12-01
SG11202111739VA (en) 2021-11-29
MX2021012544A (es) 2021-11-12
MA55752A (fr) 2022-03-02
AU2020263869A1 (en) 2021-12-23
KR20220004111A (ko) 2022-01-11
GB201905711D0 (en) 2019-06-05
EP3958863B1 (en) 2024-07-03
CA3137445A1 (en) 2020-10-29
WO2020216740A1 (en) 2020-10-29
US20220202802A1 (en) 2022-06-30
EP3958863C0 (en) 2024-07-03
PH12021552680A1 (en) 2022-07-04
JP7543304B2 (ja) 2024-09-02
BR112021021117A2 (pt) 2021-12-14
US12383544B2 (en) 2025-08-12
EP3958863A1 (en) 2022-03-02
ES2982398T3 (es) 2024-10-16
JP2022529814A (ja) 2022-06-24

Similar Documents

Publication Publication Date Title
US11407782B2 (en) Oxysterols and methods of use thereof
AU2019381750B2 (en) Methods of treatment for cystic fibrosis
EP4349840A2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
ES2791186T3 (es) Triazoles como inhibidores de receptores NR2B
KR102365535B1 (ko) 2,6-디아미노 피리딘 화합물
CN113727711A (zh) 用于治疗肾脏疾病的新化合物及其药物组合物
EA020681B1 (ru) Циклические n,n'-диарилтиомочевины и n,n'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
WO2020233618A1 (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
KR20200124655A (ko) 피라졸로[1,5-a]피리미딘 화합물의 염 및 이의 결정
PH12016502293B1 (en) Naphthyridinedione derivatives
KR20230067637A (ko) 근이영양증을 치료하기 위한 조성물 및 방법
EP3700890B1 (en) Alcoxyamino derivatives for treating pain and pain related conditions
EP3440071A1 (en) Fused heterocyclic organic compounds and uses thereof
WO2009093206A2 (ru) 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN111344291A (zh) 咪唑并吡啶衍生物及其作为药剂的用途
Li Design and synthesis of achiral and chiral imidazodiazepine (IMDZ) GABA (A) R subtype selective ligands for the treatment of CNS disorders, as well as Asthma
CN102491929B (zh) 1-羟基-2-吡咯烷酮类化合物及其制备方法和应用
WO2024129026A1 (en) The use of ezetimibe and its synthesis intermediates and isopazopanib structured molecules as anticancer agents
KR100742134B1 (ko) 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물
KR20230121762A (ko) (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태
EA018944B1 (ru) Замещенные 8-сульфонил-2,3,4,5-тетрагидро-1н-гамма-карболины, лиганды, фармацевтическая композиция, способ их получения и применения
HK40060445A (en) Methods of treatment for cystic fibrosis
HK40060445B (en) Methods of treatment for cystic fibrosis
HK40037009B (en) Alcoxyamino derivatives for treating pain and pain related conditions
HK40004131B (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211130

WD01 Invention patent application deemed withdrawn after publication